反应详情

The title compound was prepared by procedure E using 7-chloro-2-(4-methoxyphenyl)furo[3,2-b]pyridine (30.10 mg; 0.12 mmol; 1.00 eq.) instead of 7-chloro-2-(3,4,5-trimethoxyphenyl)furo[3,2-b]pyridine, and 4-methyl-1H-indol-5-ylamine (17.79 mg; 0.12 mmol; 1.05 eq.) instead of 6-amino-2,2-difluoro-4H-benzo[1,4]oxazin-3-one, and was obtained as a beige solid (27 mg, 64%). (HPLC (method F): 93%, RT: 4.07 min); 1H NMR (500 MHz, DMSO-d6) δ[ppm] 11.14 (s, 1H), 8.49 (s, 1H), 7.92 (d, J=5.5, 1H), 7.90 (d, J=8.8, 2H), 7.38 (t, J=2.7, 1H), 7.30 (d, J=8.4, 1H), 7.27 (s, 1H), 7.06 (d, J=8.9, 2H), 7.00 (d, J=8.5, 1H), 6.52 (s, 1H), 6.06 (d, J=5.5, 1H), 3.83 (s, 3H), 2.36 (s, 3H); MS (m/z) 370 [M+H]+, RT: 3.9 min.